Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma

DuBois SG, Krailo MD, Buxton A, Lessnick SL, Teot LA, Rakheja D, Crompton BD, Janeway KA, Gorlick RG, Glade-Bender J. Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Arch Pathol Lab Med. 2021 Dec 1;145(12):1564-1568. doi: 10.5858/arpa.2020-0671-OA. PubMed PMID: 33769463; PubMed Central PMCID: PMC9048754.

Molecular diagnostics play an increasing role in the diagnosis of Ewing sarcoma. The type of molecular testing used in clinical practice has been poorly described. Children’s Oncology Group (COG) trial AEWS1221 was a phase III randomized trial enrolling patients with newly diagnosed metastatic Ewing sarcoma from 2014 to 2019. Patients were required to have a histologic diagnosis of Ewing sarcoma, but translocation testing was not required. Sites provided types and results of any molecular diagnostics performed.